CStone to Lead Phase I Trials of Kimia's DDR Oncology Asset
Image
SUZHOU – November 03, 2026 -- CStone Pharmaceuticals (HKEX: 2616) will lead Phase I development of Kimia Therapeutics' potential first-in-class DNA damage response (DDR) cancer drug in mainland China and Australia, while Kimia reimburses the applicable clinical development costs.
CStone gains milestone and royalty rights without funding the trials
Under the clinical collaboration agreement, CStone is eligible for milestone payments and royalties on global net sales of the asset during the applicable royalty term. Kimia will supply the clinical drug, scientific guidance and product-related regulatory oversight. The announcement did not disclose payment amounts or royalty rates.
The asset targets the DDR pathway, which solid tumor cells rely on to survive.